Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

With Added Indication, Amarin Says Vascepa No ‘Fish Oil’ Like Omega-3s

Dec 16 2019

• By Malcolm Spicer

Red heart and a stethoscope on backgrouund - Image

Related Content

Sales Already Growing As Vascepa Secures Cardio Approval

Dec 16 2019

Omega-3 Heart Health Claims Decision: FDA Out Of Step With Industry?

Jul 01 2019

Omega-3 Marketers Back Down On Comparisons To Amarin's Vascepa

May 10 2019

Supreme Court Doesn't Bite On Amarin Appeal In Omega-3 Fair Trade Complaint

Dec 11 2019

Amarin CEO: Consumers Have Heard About Omega-3 Heart Benefits 'Too Long'

Sep 06 2019

Related Companies

Amarin Corp plc

Additional Topics

United States Dietary Supplements Ingredients FDA Advertising, Marketing & Sales Manufacturing Business Strategies Clinical Trials Commercial Companies Drug Approval Standards Approvals Policy Regulation Consumer Cardiovascular

More from Ingredients & Safety

More from HBW Insight

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window